布地奈德福莫特罗粉吸入剂联合百令胶囊治疗学龄期支气管哮喘患儿的临床疗效

Clinical Effect of Budesonide/formoterol Powder for Inhalation Combined with Bailing Capsule in Treating School-age Children with Bronchial Asthma

目的观察布地奈德福莫特罗粉吸入剂联合百令胶囊治疗学龄期支气管哮喘患儿的临床疗效。方法连续收集2014年1月—2017年4月在聊城市东昌府人民医院儿科就诊的学龄期支气管哮喘患儿220例,按照随机数字表法分为对照组和观察组,每组110例。对照组患儿给予布地奈德福莫特罗粉吸入剂治疗,观察组患儿在对照组基础上给予百令胶囊治疗;两组患儿均连续治疗24周。比较两组患儿治疗前后临床症状评分、肺功能指标、外周血嗜酸粒细胞百分比、外周血免疫球蛋白E(Ig E)水平,比较两组患儿治疗后6、12、18、24周有效率,并观察两组患儿治疗期间不良反应发生情况。结果治疗前两组患儿咳嗽症状积分和哮喘控制测试表(ACT)评分比较,差异无统计学意义(P>0.05);治疗后观察组患儿咳嗽症状积分低于对照组,ACT评分高于对照组(P<0.05)。治疗前两组患儿用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)比较,差异无统计学意义(P>0.05);治疗后观察组患儿FVC、FEV1大于对照组,FEV1/FVC高于对照组(P<0.05)。治疗前两组患儿外周血嗜酸粒细胞百分比和Ig E水平比较,差异无统计学意义(P>0.05);治疗后观察组患儿外周血嗜酸粒细胞百分比和Ig E水平高于对照组(P<0.05)。治疗后6、12、18、24周观察组患儿有效率高于对照组(P<0.05)。绘制Kaplan-Meier生存曲线显示,观察组患儿累积有效率高于对照组(P<0.001)。两组患儿治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德福莫特罗粉吸入剂联合百令胶囊治疗学龄期支气管哮喘患儿的临床疗效确切,可有效缓解患儿临床症状,改善患儿肺功能,减轻患儿炎性反应,且安全性较高。

Objective To observe the clinical effect of budesonide/formoterol powder for inhalation combined with bailing capsule in treating school-age children with bronchial asthma.Methods From January 2014 to April 2017,a total of 220 school-age children with bronchial asthma were continuously selected in the Department of Pediatrics,the People's Hospital of Dongchangfu,and they were divided into control group and observation group according to random number table,each of 110 cases.Children in control group received budesonide/formoterol powder for inhalation,while children in observation group received budesonide/formoterol powder for inhalation combined with bailing capsule;both groups continuously treated for 24 weeks.Clinical symptom score,index of pulmonary function,peripheral blood eosinophils percentage and IgE level before and after treatment,effective rate 6,12,18 and 24 weeks after treatment were compared between the two groups,and incidence of adverse reactions was observed during the treatment.Results No statistically significant differences of cough symptom score or ACT score was found between the two groups before treatment(P>0.05);after treatment,cough symptom score in observation group was statistically significantly lower than that in control group,while ACT score in observation group was statistically significantly higher than that in control group(P<0.05).No statistically significant differences of FVC,FEV1 or FEV1/FVC was found between the two groups before treatment(P>0.05);after treatment,FVC and FEV1 in the observation group were statistically significantly lager than those in control group after treatment,while FEV1/FVC in the observation group was statistically significantly higher than those in control group(P<0.05).No statistically significant differences of peripheral blood eosinophils percentage or IgE level was found between the two groups before treatment(P<0.05),while peripheral blood eosinophils percentage and IgE level in observation group were statistically significantly higher than those in control group after treatment(P<0.05).Effective rate in observation group was statistically significantly higher than that in control group 6,12,18 and 24 weeks after treatment(P<0.05).Kaplan-Meier survivorship curve showed that,cumulative effective rate in observation group was statistically significantly higher than that in control group(P<0.001).No statistically significant differences of incidence of adverse reactions was found during the treatment(P>0.05).Conclusion Budesonide/formoterol powder for inhalation combined with bailing capsule has certain clinical effect in treating school-age children with bronchial asthma,can effectively relieve the clinical symptoms,improve the pulmonary function,reduce the inflammatory reaction,with relatively high safety.